Wockhardt has informed that it enclosed the Press Release titled ‘Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873’, which is self-explanatory.
The above information is a part of company’s filings submitted to BSE.